<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <Volume-Issue>Volume 2; Issue 6</Volume-Issue>
      <Season>(Nov-Dec, 2021)</Season>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Alpelisib After Treatment with CDK4/6i and Aromatase Inhibitor: Case Report</ArticleTitle>
      <Abstract>Alpelisib is an oral drug, a phosphatidylinositol 3 kinase inhibitor (PI3K) which plays a fundamental role in the cancer process. In May 2019 Alpelisib in combination with fulvestrant was approved by FDA in treatment of PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer. Since 2020 the drug has also recommendation of European Medicines Agency (EMA). The following is a case of a patient with primary metastatic breast cancer who was treated with alpelisib in combination with fulvestrant after prior chemotherapy and an aromatase inhibitor with ribociclib, obtaining a significant clinical benefit.</Abstract>
      <Keywords>Metastatic Breast Cancer,Alpelisib,PIK3CA Mutation</Keywords>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13461&amp;title=Alpelisib After Treatment with CDK4/6i and Aromatase Inhibitor: Case Report</Abstract>
        <References>Andrand;eacute; F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pand;aacute;pai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940.&#13;
Andrand;eacute; F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pand;aacute;pai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021; 32: 208-217.&#13;
Bertho M, Patsouris A, Augereau P, Robert M, Frenel JS, Blonz C, Campone M. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. Expert Opin Drug Metab Toxicol 2021; 17: 139-152.&#13;
Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, Andrand;eacute; F. Patient-Reported Outcomes in Patients with PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol 2021; 39: 2005-2015.&#13;
Copur MS. Alpelisib to treat breast cancer. Drugs Today (Barc) 2020; 56: 357-363.&#13;
Ellis H and Ma CX. PI3K inhibitors in breast cancer therapy. Curr Oncol Rep 2019; 21: 1-9.&#13;
Fusco N, Malapelle U, Fassan M, Marchiand;ograve; C, Buglioni S, Zupo S, Criscitiello C, Vigneri P, Dei Tos AP, Maiorano E, Viale G. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Front Oncol 2021; 11: 644737.&#13;
Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol 2014; 4: 64.&#13;
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 2021; 22: 489-498.&#13;
Turner S, Chia S, Kanakamedala H, Hsu WC, Park J, Chandiwana D, Ridolfi A, Yu CL, Zarate JP, Rugo HS. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. Oncologist 2021; 26: e1133-e1142.&#13;
Wilhoit T, Patrick JM, May MB. Alpelisib: A Novel Therapy for Patients with PIK3CA-Mutated Metastatic Breast Cancer. J Adv Pract Oncol 2020; 11: 768-775.</References>